Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Clostridioides difficile toxins and associated surface/lysate antigens are the primary virulence factors and structural components of the Gram-positive bacterium C. difficile, which is the leading cause of antibiotic-associated diarrhea and pseudomembranous colitis (Crobach et al., 2016). The major toxins, Toxin A (TcdA) and Toxin B (TcdB), are large glucosyltransferases that target and inactivate Rho-family GTPases within host intestinal epithelial cells, resulting in cytoskeletal disruption, cell death, and a robust inflammatory response (Kuehne et al., 2010). Surface antigens, such as surface layer proteins (SLPs), flagellar proteins (FliC, FliD), and the protease Cwp84, play critical roles in the adhesion and colonization of the bacterium within the host gut (Péchiné et al., 2013). These molecules are significant therapeutic targets; for instance, the monoclonal antibody bezlotoxumab specifically binds and neutralizes TcdB to reduce the recurrence of C. difficile infection (Wilcox et al., 2017). Furthermore, various vaccine candidates utilize toxoids or recombinant fragments of these antigens to elicit protective immunity, aiming to prevent both the initial infection and subsequent relapses (Péchiné et al., 2013).
Neutralization of Toxin A and Toxin B to prevent intestinal epithelial damage and induction of immune responses against surface antigens to inhibit bacterial colonization.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Clostridioides difficile toxins and surface antigens (C. difficile toxins/antigens).